Heart rate and the maximum velocity of contraction of striated muscle are inversely related to species size. As mammals evolve to different sizes, adaptations are required such as slower contracting heart and skeletal muscles. Analysis of the motor domain of β-myosin from 67 mammals from two clades identifies 14 sites, out of 800, strongly associated with body mass (p<0.01) but not with the clade (p>0.05). Nine of these sites were mutated in the human β-myosin to make it resemble the rat sequence.
correspondingly, to the physiology of the muscle. In a recent study we tested the hypothesis that muscle myosin-II isoforms from mammals would have adaptations in protein sequence associated with mean body mass (Wass et al., 2016) . In this study, of ~730 sequences from 12 myosin-II isoforms from an average of 65 mammalian species, there was a strong correlation of the number of sequence changes with differences in species mass. The correlation was strongest in adult striated muscle myosins IIa and IIb and β. β-myosin is found in the heart and in slow Type I muscle fibers. Here we examine in greater detail the sequence differences within the mammalian β-myosin to establish the relationship between sequence and velocity of contraction.
The contractile properties of mammalian muscles have been widely studied but detailed mechanical and biochemical studies have been completed on only a few species and myosin isoforms. Such data are available for Type 1/β-cardiac/slow muscle fibres from four species (see Fig 1) . Each of these muscles expresses only the β-myosin isoform (MYH7), and each species has a characteristic contraction velocity that varies approximately five-fold across the set of four muscles. Moreover, it is well established for the β-myosin isoform that the contraction velocity is limited by how fast ADP escapes from the actin.myosin cross-bridge after the working stroke is completed (Walklate, Ujfalusi, & Geeves, 2016) . Data in Fig 1 show that like velocity, the ADP release rate constant differs 4-5 fold across the set of four myosins. Furthermore, the measured rate constant for ADP release from the actin.myosin complex, measured using the purified β-myosin isoform, is exactly that predicted to limit the contraction velocity (based on the detachment limited model of contraction (see Fig 1 legend) (Homsher E, Wang F, 1992; Siemankowski, Wiseman, & White, 1985; Walklate, Ujfalusi, et al., 2016) . It is therefore expected that this set of myosins will have changes in the amino acid sequence that alter the ADP release rate and hence contraction velocity.
Examining the sequences of the 800 amino acid motor domains of the four β-myosins in Fig 1 show them to be 96% identical which means there are 49 sequence differences among the four, with 34 differences between rat and human. These differences in sequence are scattered throughout the motor domain (see Fig 2 and alignment in Fig S1) . It seems likely that groups of amino acids and not a single amino acid change determine the functional differences between the β-myosins. If the correlation between body size and contraction velocity is a general phenomenon amongst mammals, as is seen for resting heart rates (Savage et al., 2007) , then a bioinformatics study of β-myosin sequences would be a way to identify which sequence changes correlate with size. We hypothesised that the variation of βmyosin contraction velocity (and rate of ADP release from the cross bridge) with the size of the mammal is due to a subset of the sequence changes observed for different mammals, and that these tune myosin velocity to that appropriate for the size of species. Here, we examine a set of 67 mammalian β-myosin sequences using a bioinformatics approach to identify a group of 12 amino acids which have the strongest association with the size of the mammal. Of these 12 amino acids, nine differ between human and rat β-myosin and we test our hypothesis through the construction and subsequent biochemical characterisation of a rat-human β-myosin chimera (hereafter referred to as chimera).
Methods

Sequence Analyses:
Amino acid sequences for the β-myosin motor from 67 different mammalian species were aligned using Clustal Omega (Sievers et al., 2011) comprising organisms from the clades Euarchontoglires (32), Laurasiatheria (30), Metatheria (4) and Afrotheria
(1). The start and end points of the motors in Homo sapiens were considered to be residues 1 and 800 (based on UniProtKB -P12883).
Statistical analysis:
For each position in the alignment that had more than one amino acid present, species masses were compared between the two highest frequency amino acids at that position using the Mann-Whitney U test, a nonparametric two-sample test. Multiple testing was accounted for by applying the Bonferroni correction. To avoid very imbalanced comparisons, the analysis was not run if the frequency of the second amino acid was less than 10% of the frequency of the most frequent one. Where more than two amino acids were present at an alignment position, only the two most frequent amino acids were considered. See Fig S3 for details of sites with more than 2 amino acids.
Alignment positions were divided into three groups: those with an adjusted p-value (padj) less than 0.01 (with Bonferroni correction applied this is equivalent to a p-value of p= 9.50x10 -04 ), those with 0.01 < padj < 0.05 (5% significance threshold equivalent to p=9.62x10 -4 ), and those with a padj >0.05. In addition, the two highest frequency amino acids were coded as 0 and 1 and a logistic regression model was fitted with log(mass) as the explanatory variable (Fig 3 & Supplementary Fig 2) . In order to overlay these residue plots, as the coding of the amino acids as 0 and 1 was arbitrary, it was done in such a way that the slope of the fitted logistic regression line was positive ( Fig 3) . The value of mass at which the two amino acids were predicted to be equally likely to occur was estimated from the regression line.
For each alignment position, a 2x2 table was constructed classifying the species by amino acids present (most frequent and second most frequent) and clade. Fisher's exact test was used to test whether these two factors were associated. The residue and -log10 of the P-value from the Fisher's exact test were plotted to identify residues for which the amino acid variation was likely to have resulted from clade associated changes. The residue and -log10 of the p-value from the Mann-Whitney U test were also plotted to determine when residue variation was likely attributed to mass changes.
Finally, the -log10 p-values obtained from both tests were plotted against each other.
For each of these plots, lines at positions of the Bonferroni adjusted p-values 0.01, and 0.05 were added to assess the confidence in each residues association with mass or clade.
All statistical analyses were run in R (R Core team, 2018).
Molecular Biology of the chimera:
A pUC19 plasmid containing the human β-myosin motor domain gene was digested with NsiI and NgoMIV to excise DNA encoding for residues 310 -599 of the human β-myosin. This region was replaced with a complementary pair of synthetic oligos encoding for the same region, but with the nine amino-acid substitutions listed (Ala326Ser, Ser343Pro, Leu366Gln, Ile421Ala, Thr424Ile, Ala430Ser, Arg434Lys, Phe553Tyr, Pro573Gln). The subsequent clone was confirmed by sequencing. This chimera gene was cloned into a pShuttle CMV vector to allow recombinant replicationdeficient adenovirus production, as previously described (Deacon et al 2012) .
Rat β-myosin S1 was prepared from soleus muscle which was dissected immediately post mortem and stored on ice. The muscle was homogenised into Guba-Straub buffer and left to stir for 30 minutes. After centrifugation at 4600 RPM for 30 minutes at 4 °C, the supernatant was subject to myosin precipitation as described in (Margossian, SS. Lowey, 1982) . The resulting myosin was digested with 0.1 mg chymotrypsin per ml of solution and left to stir for 10 mins exactly, at room temperature. To stop the digestion, 0.5 mM phenylmethylsulfonyl fluoride (PMSF) was added and the solution left to stir for 10 minutes. The digested myosin solution was dialysed into the low salt experimental buffer overnight (25 mM KCl, 20 mM MOPS, 5 mM MgCl2, 1mM DTT, pH 7.0). Precipitated myosin and light meromyosin was pelleted and removed via centrifugation at 12,000 RPM for 10 minutes, with the supernatant containing the purified soleus S1. SDS-Gels of the purified protein were run and compared to the expressed human β-myosin and chimera S1.
Stopped flow:
Kinetic measurements for S1 of chimera, human β-myosin and rat soleus myosin were performed as described previously (Marieke J Bloemink et al., 2013; Deacon et al., 2012; Walklate, Vera, Bloemink, Geeves, & Leinwand, 2016) . Solutions were buffered with 25 mM KCl, 20 mM MOPS, 5 mM MgCl2, 1 mM DTT at pH 7.0, and measurements were conducted at 20 °C on a High-Tech Scientific SF-61 DX2 stopped-flow system.
Traces were analysed in Kinetic Studio (TgK Scientific) and Origin.
In vitro motility assay:
Motility assays were performed essentially as described previously (Adhikari et al., 2016; Aksel et al., 2015) . Briefly, flow chambers were constructed with coverslips coated with nitrocellulose mounted on glass slides. Reagents were loaded in the following order: 1) SNAP-PDZ18 affinity tag; 2) BSA to block the surface from nonspecific binding; 3) S1 of human β-myosin or the chimera with an eight amino acid Cterminal affinity clamp; 4) BSA to wash the chamber; 5) rhodamine-phalloidin-labelled rabbit actin; 6) an oxygen-scavenging system consisting of 5 mg/ml glucose, 0.1 mg/ml glucose oxydase and 0.02 mg/ml catalase 7; 2 mM ATP. Partially inactivated myosin heads in S1 preparations were removed by incubating with a 10-fold molar excess of actin and 2 mM ATP for 15 minutes, then sedimentation at 100,000 RPM for 15 minutes. Supernatant was collected containing active myosin heads. All solutions were diluted into 25 mM imidazole, 25 mM KCl, 4 mM MgCl2, 1 mM EGTA, 1 mM DTT, pH 7.5. Actin filaments were detected using a widefield fluorescence imaging system (described in (Johnson, East, & Mulvihill, 2014) ) with UAPON 100XOTIRF NA lens (Olympus) and QuantEM emCCD camera (Photometrics). The system was controlled and data analysed using Metamorph software (Molecular Devices, Sunnyvale, USA).
Assays were performed at 20 °C and were repeated with three fresh protein preparations, with at least three movies of 30 second duration, recorded at a rate of 0.46 sec per frame. Individual velocities were determined from motile filaments that demonstrated a smooth consistent movement over 10 frames (4.6 sec). 100 individual measured velocities were used to calculate the mean velocity for each recombinant myosin.
Results
The alignment of the β-myosin sequences from four mammals (Fig 2 & Fig S1) demonstrates that while the sequences are highly conserved, the 49 sites of variation among the species are scattered throughout the motor domain. High levels of variation are found in the N-terminal domain (1-60) and near the surface loops, Loop hypervariable across the larger myosin family (J. Spudich, 1994) . The broad distribution of the sequence variants means that an experimental approach to define which residue changes are linked to the change in ADP release (and hence velocity of contraction) is too complex to consider. Instead, we used a bioinformatics-based approach to identify the residues most likely to be linked to the change in velocity of contraction.
Distinguishing between variation due to clade and body mass:
We analysed 67 complete sequences of the β-myosin motor domains from species ranging in size from 7g (Brandt's bat, Myotis brandtiibat) to 42,000 kg (sperm whale, Physeter catodon). Of these, about half were Euarchontoglires (32, e.g. rodents and primates) and half were Laurasiatheria (30, e.g. bats, ungulates, cetaceans). We used this set of sequences to distinguish between sequence changes that had a high probability of association with the clade vs those that correlated with the size of the animal (see Methods). A total of 171 sites were identified where a sequence change occurred. At the majority of these positions, variation occurred in a small number of species and is unlikely to be associated with changes in function relevant to body mass, so 119 positions where a sequence change was present in less than 10% of the species were excluded. This included 84 sites where a change occurred in only one species, while changes in two species occurred at 20 sites and in three species at four sites.
The remaining 52 sites of variation were analysed to distinguish between changes that correlated with clade and those that correlated with body mass (as illustrated in Fig 3 for four sites with the remaining plots in Supp Info - Fig S2) . In most cases, only two residues were observed at each specific site; in the small number of cases (11/52) with multiple amino acids, only the two most frequent residues were considered. The identity of the two most frequent amino acids were coded as 0 and 1 and a logistic regression model was fitted with log(mass) as the explanatory variable (Fig 3, Fig S2; see methods) to model the transition between residues. Data for four sites are presented in Fig 3 and of the sites shown, two had a strong correlation with species body mass (the amino acid common in small mammals is given first P343S, I349P; padj ≤ 0.01. Note the adjusted one percent significance threshold is p= 9.50x10 -4 and the 5% significance threshold is p=9.62x10 -4 . padj will be used to indicate the adjusted significance threshold), and each has a distinct midpoint mass for the transition between the two amino acids. In contrast, I125V has a low association with mass (p = 0.03) and M77L has an intermediate association (p= 9.50e-04), however both M77L and V125I have a strong association with the clade (Fig 4) ; L77 and I125 are found almost exclusively in Laurasiatheria.
Overall, only 12 sites had a very strong association with clade (padj ≤ 0.01) and a further two were significant at the five percent level (padj ≤ 0.05; Fig 4A) . Some of these residues occur in two groups; one group of four in the N terminal region below residue 135 (4, 11, 52, 77, 110, 125) and four residues near surface loop 2 (610, 616, 627, 629) . The remaining four are at D208E, E509T, T585I and I684M. Twenty positions were strongly associated (padj ≤ 0.01) with body mass and a further four were significantly associated at padj ≤ 0.05 ( Fig 4B) . Nine positions were associated with both clade and body mass ( Fig 3C) , which is likely to represent that the very largest mammals (body mass > 500 kg) in the data set are all Laurasiatheria (Fig S5) .
Twenty residues had a very strong association with mass, p ≤ 1.92x10 -4 (1% significance threshold, adjusted for multiple testing) and a further four significant at the five percent level (p < 9.62x10 -4 ; Fig 4B) . Twelve of these 24 sites occur in the known hypervariable regions, four in the N terminal region ( 11,15,52,65, bold residues also occur in the clade list), one in loop 1 (D208E), and a further six occur in or near loop 2 (607, 610, 616, 627, 629, 631) ) and one at I684M. The remaining 12 sites (Table 2) group into three sets of four; most with padj ≤ 0.01 (coloured in Fig 4 & 5) . Comparing the strength of association between clade and body mass, these 12 sites, are strongly associated with body mass but not with clade ( Fig 4C) . Hence, we propose that these 12 positions are likely to be important in determining the β-myosin velocity of contraction. At eight of the twelve positions only two amino acids are observed, one position contains three amino acids, although the third is only present once (residue 366). Multiple amino acids (4-7) were observed at the remaining three positions. For two of the positions, 421 and 424, this reflects a subset of the species from one clade having an alternate amino acid in some of the larger species (see Sup Fig S3) .
The first group of residues is in a region 331-371 (Orange in Fig 4 and 5) adjacent to the exon 7 region of Drosophila myosin II (and the "linker region"). This region is one of four exons in the single myosin II gene of Drosophila which are alternately spliced to generate all isoforms of myosin II in Drosophila (Bernstein & Milligan, 1997) . We 
Experimental testing of the computational predictions:
We have previously expressed the motor domain of human β-myosin in mouse C2C12 muscle cells and isolated the protein using His tags attached to the co-expressed human light chain. This is currently the only way to express mammalian striated muscle myosin motors but is complex and time consuming and yields just a few mg of protein (Qun Wang Carole L. Moncman and Donald A. Winkelmann, 2003; Rajani Srikakulam and Donald A. Winkelmann, 2004; Resnicow et al., 2010) . To test the hypothesis that the highlighted group of 12 residues are responsible for a significant part of the adjustment of ADP release rate constant, we generated a chimeric humanrat β-myosin motor domain where the nine positions (of the 12) that vary between human and rat were replaced with the amino acid present in rat (A326S, S343P, L366Q, I421A, T424I, A430S, R434K, F553Y, P573Qhuman residue number and amino acid listed first). The other three positions are the same in rat and human (354, 576 & 587) . At residue 421 we replaced Ile with Ala as present in rat, although Ser is present in most of the smallest mammals (See Fig S3) . Fig 1, the velocity of contraction for β cardiac/Type I slow muscle fibres in rat and humans differ by a factor of ~4. Given that these residues have a range of transition masses (see Fig 6) the hypothesis is that each of these nine residues will contribute a fraction of the difference between the rat and human β-myosin ADP release rate constant and hence, velocity. With all nine residues changed, our prediction is that the differences in the rate constant should be large enough to be easily detectable.
As shown in
The S1 fragment of human β-myosin and the chimera were expressed in C2C12 cells and purified with the human essential light chain attached (see Fig 5) . Few details of the kinetic characterisation of the rat β-myosin S1 have been published (M. J. Bloemink, Adamek, Reggiani, & Geeves, 2007) . The rat β-myosin S1 was therefore purified from rat soleus muscle to use as a comparator for the chimera. The supplementary data include the SDS PAGE of all three proteins used in this study and demonstrates that all three proteins are pure and contain the appropriate light chains ( Fig S4) .
As a test of the behaviour of the chimeric protein, the ATP-induced dissociation of the chimera from pyrene labelled actin was monitored and compared to the recombinant human and the native rat S1. A typical transient is presented inset in Fig 7B and the observed amplitude of the signal change was the same for all three proteins. The similarity of observed amplitudes of the pyrene signal changes for the chimera, human and native rat proteins indicates that the chimera binds actin and releases it on ATP binding as for the human and rat S1. This is consistent with the chimera being a fully folded and active protein. A plot of the observed rate constant (kobs) vs [ATP] gives a straight line which defines the apparent 2 nd order rate constant for the reaction ( Fig   7B) and appears the same for all three proteins. The observed rate constant of this reaction has been defined for many myosins and has two components, kobs = [ATP] K'1k'+2. The reaction is sensitive to both the affinity of ATP for the complex (K'1) and the efficiency with which ATP induced a major conformational change in the myosin (k'+2). This involves the closure of switches 1 and 2 onto the ATP and the opening of the major cleft in the actin binding site of myosin. The absence of any change in K'1k'+2 is consistent with a well preserved nucleotide pocket and a preserved communication pathway between the ATP binding pocket and the actin binding site.
The affinity of ADP for actin.S1 was measured in a competition assay with ATP ( Fig   7C) and the affinity of ADP for the rat actin.S1 complex (14 μM) was 2.3 fold weaker than for the human WT protein (6.3 μM). These values are consistent with published values (Nag et al., 2015) . The chimera was distinct from the human S1 and indistinguishable from the rat S1. To confirm this result the ADP release rate constant was measured directly by displacing ADP from actin.S1.ADP through addition of an excess of ATP. The results (Fig 7D) for human and rat S1 are again consistent with published values with ADP leaving the rat complex at ~ 2X the rate of the human complex (107 vs 59 s-1). The chimera was indistinguishable from the rat S1. As predicted, the amino acids introduced into the human β-myosin motor domain weaken ADP affinity for actin.myosin by accelerating ADP release to make the human βmyosin S1 behave like the rat β-myosin S1.
Footnote: The inset shown in Fig 7D; a complication of the ADP displacement measurement is that ADP displacement from human β-myosin occurs in two phases (fast and slow). The fast phase corresponds with ADP released at the end of the normal ATPase cycle while the slow phase is a trapped ADP which is released much slower and at a much rate slower than the overall cycling. This is therefore a dead-end side branch of the pathway commonly seen in slow muscle & non muscle myosins (M. J. Bloemink, Adamek, Reggiani, & Geeves, 2007; Deacon et al., 2012; Nyitrai & Geeves, 2004) . The fraction of ADP trapped in this way is characteristic of each myosin. The rat β-myosin S1 has no apparent slow phase, the human has ~10% of ADP released in the slow phase while the chimera has a larger fraction (~40%) of the total ADP released in the slow phase. The role of the substituted amino acids in the slow phase requires further study, but the reader is referred to the literature for a broader study of this phenomena.
Motor activity of the recombinant human β-myosin S1 and the chimera protein was measured using an in vitro motility assay ( Fig 7A) . This assay determines the myosinmediated velocities of fluorescent actin-filaments moving on a nitrocellulose-coated slide surface. The human WT β-myosin moved actin at a velocity of 0.49 μm.s -1 at 20 °C.. Introduction of the nine rat amino acids into the WT protein increased the mean filament velocity by almost 2-fold, from 0.49 μm.s -1 to 0.9 μm.s -1 for the chimera, which is consistent with predictions from the ADP release-rate data (predicted velocity assuming a 10 nm step size 0.59 and 1.00 μm.s -1 ). Our human S1 velocity was similar to the 0.612 μm.s -1 value reported by Ujfalusi et al, which was measured at 23 °C (Ujfalusi et al., 2018) . A similar velocity of 0.378 μm.s -1 was reported for full length human-β myosin at 25 °C (Pellegrino et al., 2003) . who aslo reported a velocity of 0.624 μm.s -1 for the rat. This gives a rat/human ratio of 1.65, very similar to our chimera/human ratio (1.84).. The motility assay was not performed for the rat S1 as we do not have an expression system for the protein. The native rat S1 has only a single light chain and lacks a tag to attach the protein to the surface. The rat protein will not therefore give a valid comparable measurement. However, it is known from the literature (Table in Fig 1 & references therein) that the rat protein moves 3-5 times faster than the human protein, depending upon the exact measurement conditions.
Discussion
Our analysis confirmed our hypothesis that there is a set of sequence changes in the β-cardiac myosin, among mammals, that have a high probability of association with species mass. In the 67 species examined 52 sites in the motor domain the residue present varied in more than six species. Of these 52 sites a set of 24 sequence changes had the strongest association with mass (p<0.05) and little association with clade (p>0.05). These sites were found throughout the motor domain but we noticed three clusters of four residues (Fig 4) within the group that would allow a cloning approach to test if these residues do play a role in adjusting the velocity of muscle contraction. Of these 12 residues, nine differ between the rat and human β -myosin.
We have an expression system for the human myosin motor domain and therefore made a human/rat chimera by exchanging these nine residues.
The chimera displayed a two-fold weakening of ADP binding to actin.myosin due to a two-fold acceleration of the rate constant controlling ADP release from the complex.
The two fold faster ADP release rate constant, since it is believed to limit contraction velocity, predicts a two-fold acceleration of the velocity of muscle contraction and a two-fold acceleration of the speed at which actin would move over a bed of myosin.
The motility assay confirmed this prediction. The mutations could have caused a generalised loss of nucleotide binding to the protein but a control examining the ability of ATP to bind to actin.myosin and displace actin was indistinguishable among the three proteins ( Fig 7B) .
Thus our bioinformatics approach has successfully identified nine residues with a role in modulating the velocity of muscle contraction which have been selected over time to adjust the velocity to that required for the slower contraction in human vs rat hearts.
Before considering the sites in the motor domain of myosin where these changes occur we should consider the role of the remaining 40 sites. As shown in Fig 4C, 21 sites have no apparent association with clade or mass and therefore the functional significance of these residue changes remains undefined. Eight sites have a strong association with clade but no or only modest association with mass. A further four sites had a strong association with both clade and mass. Each of these four sites that have strong association with both mass and clade along with the four sites, which were not made in the chimera, with a strong association with mass may contribute to the changes in contraction velocity between mammals. Our approach here was to establish the principle of the effect rather than delineate the contribution of every sequence change. Thus we focussed on three groups of amino acids As stated in the introduction making single point mutations in the motor domain is unlikely to give sufficient experimental resolution to define the contribution of each residue to the 2-3 fold changes we were expecting between rat and human. However, groups of changes could possibly define the relative contributions of each of the three groups of residues. At the moment the complexity and expense of expressing the protein in mouse cell lines prohibits a larger scale study.
What was also unexpected was the finding that a set of ~ 20 residues with the highest correlation with mass are predicted to have a narrow mass range over which each sequence change is found ( Fig 6) . Additionally, each of the residues has its own distinct midpoint for the transition. This implies that as mass increases, there is a limited number of ways in which the ADP release can be modified step-wise and mammals from distinct clades utilise the same set and order of sequence changes. This is a prime example of convergent evolution in the two clades.
None of the mutated residues are in direct contact with the nucleotide binding pocket ( Fig 5) , thus suggesting that the mutations have allosteric effects. Four of the changes occur in helix-O, a long helix in the upper 50 kDa domain that links the actin binding site (cardiomyopathy loop) with switch 2 in the nucleotide binding site. It is therefore in a position to influence the communication between these two important functional sites. However, the available crystal structures published from a variety of myosins show this helix to move with the whole of the upper 50 kDa domain (e.g. see Fig 7 in M. Bloemink et al., 2014) . The other two groups or changes (three residues in the upper 50 kDa domain and two in the lower 50 kDa domain) are not close to each other in space. Understanding how the changes (for the most part conservative substitutions) in these regions alter the behaviour of the myosin will require a detailed molecular dynamics study. Seven of the twelve positions include amino acid changes that introduce or remove side chains that are capable of forming hydrogen bonds, thus it is possible that the sequence changes result in minor changes to hydrogen bonding networks in the protein. None of these sites are appear in the ClinVar web site as sites of mutations in human β-myosin associated with cardiomyopathies.
The results presented here show how a direct link between an organism's physiology and a specific protein sequence allows the exploration of how selection may have adapted protein function to match the physiological requirements. The observation that the same set of amino acids have independently changed in two clades suggests constraints on the way a protein sequence can adapt whilst maintaining function. A wider study of muscle myosin sequences may show if different isoforms use the same or distinct sets of amino acids to adapt to the same selective pressure.
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Data availability
Source data files are available from Figshare -10.6084/m9.figshare.8275406 Table 1 . Comparison of ATP and ADP binding parameters of native rat S1, and the C2C12 cell expressed human β-myosin and chimera S1. Errors reported are SEM, except for motility which is the HWHM of the normal distribution.
Rat native S1
Chimera S1 Human S1 Chimera/Rat ratio Chimera/Human ratio ATP binding to A.S1
(µM -1 s -1 ) (Deacon, Bloemink, Rezavandi, Geeves, & Leinwand, 2012) , the rat from this study. NB the value for human k-ADP at 12 °C was estimated from an Arrhenius plot of values between 20 and 10 °C (M. Bloemink et al., 2014) . These values are consistent with rat and porcine β-HMM data carried out at 100 mM KCl and 15 °C (Pereira et al., 2001) . Vo data for rat, rabbit & human (Pellegrino et al., 2003 ), bovine (Toniolo et al., 2005 .
Figure 1. The relationship between the predicted and measured parameters for
four slow/beta cardiac myosin isoforms. Figure adapted from (Nyitrai & Geeves, 2004) . In terms of the actin myosin cross bridge cycle the dominant model proposes that the maximum velocity (V0) is limited by the lifetime of the strongly attached force holding state (τ) the "detachment limited model" (V0 = d/τ where d is the working stroke of the cross bridge; assumed here to be 5 nm (Siemankowski, Wiseman, & White, 1985) . For the mammalian, β-cardiac/slow-muscle myosin isoform, it is well established that τ is defined by the rate constant controlling ADP release k-ADP = 1/τ
Figure 2. Distribution of sequence variations for the β-myosin sequences listed
in Figure 1 . The sequence which is ~96% conserved was divided into blocks of 30 residues and the no of sites within that group showing a change is plotted. The maximum number is six residues in region 1-30 reflecting the high degree of identity among the four sequences. the nucleotide binding site in marine blue, and the converter region in yellow. The three groups of residues investigated are highlighted and labelled in orange (326, 343, 349, 366), purple (421, 424, 430, 434) , and red (553, 569, 573, 580) in each plot, and those that were switched are in bold and underlined.
Figure 6. Residue mass transition plots.
Overlapping binomial regression mapping the transition of the most frequent amino acid at positions in the motor region of βmyosin to the second most frequent amino acid at that position for residues at three Bonferroni adjusted P-value significance values. These are P < 0.0005 (A), P = 0.05-0.0005 (B), P > 0.05 (C). The amino acids (AA) that occur most frequently and second most frequently are at the extremes of the y-axis. The three groups of residues from pyrene-actin.S1.ADP complex by an excess of ATP. 2 mM ATP was mixed with 250 nM S1 which was pre-incubated with 500 nM pyrene-actin and 100 µM ADP. k+ADP values for the 3 proteins are given 7D . Inset showing data on a longer log time scale showing the slow phase components of the transients. The average values from 3 independent measurements for experiments shown in B, C and D are summarised in Table 1. 
